Work

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

Year: 2013

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v122.21.873.873

Authors: David L. Porter, Michael Kalos, Noelle V. Frey, Stephan A Grupp, Alison W. Loren, Christina Jemision, Joan Gilmore, Holly McConville, James Capobianchi, Lester Lledo, Anne Chew, Angela Shen, Patricia A. Wood, Manuel Litchman, Zhaohui Zheng, Bruce L. Levine, Carl H. June

Institutions: Abramson Cancer Center, University of Pennsylvania, Children's Hospital of Philadelphia, Novartis (United States)

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4233975944

FWCI: 1.901

Cites:

Cited by: 20

Related to: 10